Lipoprotein (a) measurements for clinical application
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific antibodies directed to apo(a) more difficult and poses significant challenges to the development of immunoassays to measure its concentration in plasma or serum samples. Apo(a) is extremely variable in size not only between but also within individuals because of the presence of two different, genetically determined apo(a) isoform sizes. Therefore, the antigenic determinants per particle available to interact with the antibodies will vary in the samples and the calibrators, thus contributing to apo(a) size-dependent inaccuracy of different methods. The lack of rigorous validation of the immunoassays and common means of expressing Lp(a) concentrations hinder the harmonization of results obtained by different studies and contribute to the lack of common cut points for identification of individuals at risk for coronary artery disease or for interventions aimed at reducing Lp(a) levels. The aim of our review is to present and critically evaluate the issues surrounding the measurements of Lp(a), their impact on the clinical interpretation of the data, and the obstacles we need to overcome to achieve the standardization of Lp(a) measurements.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels [88-90].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [90]
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Sharrett, A. R., Ballantyne, C. M., Coady, S. A., Heiss, G., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 944
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 558
Cited by
Items 201–300 of 337
Afanasieva, O. I., & Pokrovsky, S. N. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-5-101-108 · Cited by 10
Lin, Y., Wang, L., Hung, K., Chang, C., Wu, L.-C., Ho, C., & Chen, J. (2022) · Nutrients · doi:10.3390/nu14051108 · Cited by 9
Fang, S., Deng, C., & Zhao, R. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44003 · Cited by 10
“Furthermore, due to molecular weight differences among apo(a) isoforms, there is no fixed conversion factor between mass-based units (mg/dL) and particle-based units (nmol/L) [88].”
Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review
Mwipatayi, B. P., Dodd, J. E., Bazlee, A. H. A., Stratford, G., Lee, B., Mori, T. A., Watts, G. F., Armari, E., Wong, J., & Schlaich, M. P. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s555127 · Cited by 10
“Elevated Lp(a) levels highlight its potential as a therapeutic target for cardiovascular diseases.”
Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial
Cho, L., Nordestgaard, B. G., Chang, B., Frndak, S., Cao, H., Wang, J., Manning, B., Wolski, K., & Nissen, S. E. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120796 · Cited by 8
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.03.002 · Cited by 14
Fogacci, F., Арманович, А. А., Cesaro, A., Bernardi, M., Perone, F., Giovannini, M., & Cicero, A. F. G. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.106994 · Cited by 6
Wang, H., Jin, X., Lin, F., Chen, G., Lin, M., & Ma, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02632-4 · Cited by 7
“In the obese population, HDL function is severely impaired because of chronic inflammation and glycation modifications, necessitating a lower threshold to compensate for the reduced cholesterol efflux capacity [35, 36].”
Lipoprotein(a) and the risk of recurrent coronary heart disease: the Dubbo Study
Simons, L. A., & Simons, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2214434 · Cited by 6
Paragh, G., Zilahi, P., Kolozsvári, L. R., Lőrincz, H., Fülöp, P., & Harangi, M. (2024) · Life · doi:10.3390/life14030374 · Cited by 9
“…it Life 2024 , 14 , 374 3 of 14 may be overestimated in individuals with large isoforms and low levels when one uses a single reference standard [12]. level of Lp(a) may be underestimated in individuals with small isoforms and high levels, while it may be overestimated in Because of these…”
BackgroundInfluentialPuato, M., Zambon, A., Nardin, C., Faggin, E., Pesavento, R., Spinazzè, A., Pauletto, P., & Rattazzi, M. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/5546800 · Cited by 7
“Lp(a) levels were evaluated using a standard immunochemical-based assay with reference ranges < 30mg /dl or <75 nmol/l [16, 17].”
MethodEvolving guidelines on lipoprotein(a)
Boffa, M. B., Koschinsky, M. L., & Hegele, R. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001016 · Cited by 5
Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities
Enkhmaa, B., Roshanravan, B., & Berglund, L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000968 · Cited by 7
“35 – 37 A number of guidelines have addressed clinical management of Lp(a) including levels associated with CVD risk.”
Hober, A., Rekanovic, M., Forsström, B., Hansson, S., Kotol, D., Percy, A. J., Uhlén, M., Oscarsson, J., Edfors, F., & Miliotis, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281772 · Cited by 6
Lipoprotein(a) and Atherosclerotic Cardiovascular Diseases: Evidence from Chinese Population
Li, J. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000059 · Cited by 5
Simental‐Mendía, L. E., Sánchez‐García, A., & Guerrero‐Romero, F. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04935-z · Cited by 5
“Elevated lp(a) concentrations were defined by levels > 50 mg/dL [15].”
BackgroundBarbieri, G., Cassioli, G., Kura, A., Orsi, R., Magi, A., Berteotti, M., Scaturro, G. M., Lotti, E., Gori, A. M., Marcucci, R., et al. (2024) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24998 · Cited by 5
“28,29 To deal with this issue, since > 90% of the variance in Lp(a) levels is genetically determined, with KIV2 repeat polymorphism being the major determinant, several groups attempted to demonstrate that the characterization of this CNV can be used to indirectly assess Lp(a) levels and to…”
BackgroundSolnica, B., Sygitowicz, G., Sitkiewicz, D., Jozwiak, J. J., Kasperczyk, S., Broncel, M., Wolska, A. T., Odrowąż‐Sypniewska, G., & Banach, M. (2024) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0054.4954 · Cited by 9
Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation
Onat, A., Kaya, A., & Ademoğlu, E. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1417839 · Cited by 5
“L (~54 mg/dL) in African-Americans, and 40 nmoles/L (~17 mg/ dL) in a Japanese population [14].”
BackgroundCurrent concept and residual issues of lipoprotein(a) determination for a cardiovascular risk factor
Yoshida, H., Hirowatari, Y., Ogura, M., & Harada‐Shiba, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13700 · Cited by 5
Šuran, D., Kanič, V., Kokol, P., Završnik, T., Verhnjak, F., Žlahtič, B., Sinkovič, A., & Naji, F. H. (2024) · Diagnostics · doi:10.3390/diagnostics14232757 · Cited by 4
Galani, A., Zikopoulos, A., Potiris, A., Moustakli, E., Stavrakaki, S. M., Paraskevaidi, M., Skentou, C., Zikopoulos, K., Drakakis, P., & Stavros, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124134 · Cited by 4
Legget, M. E., Earle, N. J., Poppe, K., Bradbury, K. E., Pilbrow, A. P., Logue, G., Choi, Y. C., Devlin, G., Gladding, P. A., Grey, C., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120516 · Cited by 4
Safety of low lipoprotein(a) levels: the FOURIER trial
Gencer, B., Giugliano, R. P., Ran, X., Mach, F., Stroes, E. S. G., Gouni‐Berthold, I., Češka, R., Владиславович, Е. М., Jukema, J. W., Jensen, H. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag398 · Cited by 5
To test, or not to test: that is the question for the future of lipoprotein(a)
Ellis, K. L., Chakraborty, A., Moses, E. K., & Watts, G. F. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1596799 · Cited by 4
“Marcovina and Albers [78] have suggested imputations to derive ethnic-specific Lp(a) concentrations for individual patients, but this requires further evaluation.”
BackgroundInfluencia de la concentración de triglicéridos en la lipoproteína(a) en función de la dislipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.11.005 · Cited by 7
Saraiva, M., Garcez, J. B., da Silva, B. T., Ferreira, I. P., Oliveira, J. C., & Palma, I. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02433-9 · Cited by 5
Sheng, L., Yang, Y., & Zhou, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01621-y · Cited by 5
“Moreover, the lack of uniformity in reporting cutoff values for high Lp(a) levels further hinders the interpretation and application of findings [46].”
Lipoprotein(a)—When to Screen and How to Treat
Patel, N., Mittal, N., Choubdar, P. A., & Taub, P. R. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00698-8 · Cited by 4
Mullan, B. A., Chan, D. C., Charlesworth, J., Moullin, J. C., Schultz, C. J., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000609 · Cited by 4
Simons, L. A., Simons, J., Friedlander, Y., & McCallum, J. C. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.04.012 · Cited by 4
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
“Differences in Lp(a) levels between individuals can vary by a factor of ~ 1000 [19].”
BackgroundUtility of Advanced Lipoprotein Testing in Clinical Practice
Feingold, K. R., & Grünfeld, C. (2016) · Europe PMC (PubMed Central) · Cited by 7
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 6
Wang, Z., Zhang, J., & Tang, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02800-6 · Cited by 3
“Using an immunoturbidimetric assay, baseline Lp(a) in circulation was quantified by allowing the antigen in the sample to bind anti-human Lp(a) antibodies in the reagent, producing an immune complex whose turbidity reflects the concentration present [26].”
Lowering of Lipoprotein(a) with Olpasiran
Amo-Tweneboah, C., & Kaur, G. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x428489260113103704 · Cited by 6
Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting
Jeevanathan, J., Blom, S., Olsén, T., Holven, K. B., Arnesen, E., Trydal, T., Nordestgaard, B. G., Sovershaev, M., Chen, Y., Retterstøl, K., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100726 · Cited by 3
“Since each individual carries two different isoforms with numerous possible combinations, the isoform composition in the blood sample often differs from the isoform composition in the standard curve, further complicating the accuracy of the assays [7].”
BackgroundFang, Z., Wang, R., Yang, C., Wang, D., Chen, W., Lin, B., Gong, D., Li, S., Liang, J., Liang, X., et al. (2021) · Disease Markers · doi:10.1155/2021/7879508 · Cited by 3
Hiraishi, C., Matsui, S., Kojima, T., Sato, R., Ando, K., Fujimoto, K., & Yoshida, H. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64261 · Cited by 5
Clouet-Foraison, N., Vaisar, T., & Marcovina, S. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_19 · Cited by 3
Self-citationLipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
Engler, R. J. M., Brede, E., Villines, T. C., & Vernalis, M. (2019) · PubMed · Cited by 4
Refining Lipoprotein(a) Associated Cardiovascular Risk in Women
Rosenson, R. S., & Marcovina, S. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.011 · Cited by 3
“The different number of KIV2 repeats, varying among individuals from as few as 2 to >40, constitutes a serious challenge in development of assays to quantify Lp(a) in human samples with the results that the Lp(a) levels are underestimated or overestimated based on the size of apo(a) in the samples compared with the as…”
BackgroundSelf-citationHamid, I. H., Muppa, N., Modi, D., Sompalli, S., Habib, I., Chaudhari, S. S., Arsalan, M., & Allahwala, D. (2024) · Cureus · doi:10.7759/cureus.72776 · Cited by 3
“Lp(a) is a complex lipoprotein particle, consisting of an apolipoprotein B (ApoB)-containing low-density lipoprotein (LDL) molecule attached to a unique glycoprotein, apolipoprotein(a) (Apo(a)) [5-6].”
Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2025-0034 · Cited by 2
“In view that determination of total Lp(a) mass is very heterogeneous and challenging, a target value in nmol/L was assigned to Lp(a) based on the size of the apo(a) polymorhism, which is the Lp(a) component most commonly measured directly by immunoassays [48].”
Li, Q., Xu, J., Xiong, Z., & Ying, Q. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112940 · Cited by 2
Phan, H. T., & Ho, M. T. T. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1669234 · Cited by 3
Jang, A. Y., Lee, J. H., Lee, S., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0388 · Cited by 2
“108)109) These repeats produce Apo(a) isoforms of differing sizes, complicating accurate quantification.”
Lp(a) in the Horizon of Diagnostics and Therapy
Formisano, P., Vianello, E., Dozio, E., Tacchini, L., Romani, L. R., Frati, L., Curcio, F., Bellet, M. M., & Corsi-Romanelli, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010290 · Cited by 4
“Therefore, early and isoform-sensitive methods yielded considerable discrepancies between laboratories, complicating comparisons across studies and limiting clinical interpretation [6,7].”
Jang, A. Y., Lee, J. H., Lee, S.-G., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.2 · Cited by 2
Lipoprotein (a) and Coronary Atherosclerosis in Intracoronary Imaging - YELLOW II – Lp(a) Study
Gurevitz, C., Vengrenyuk, Y., Minatoguchi, S., Yasumura, K., Hooda, A., Krishnan, P., Moreno, P., Narula, J., Sharma, S. K., Rosenson, R. S., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07850-1 · Cited by 2
“Third, Lp(a) was measured by a mass assay that may be influenced by the variable size of the apo(a) isoforms, leading to potential misestimation of atherogenic burden [31].”
Mwipatayi, B. P., Dodd, J., Bazlee, A. H. A., Jones, G., Verhagen, H. J. M., Milner, R., Mori, T. A., Watts, G. F., Golledge, J., & Schlaich, M. P. (2026) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2026.05.016 · Cited by 2
Nageswaran, G., Chidambaram, V., Kumar, A., Doukky, R., Leucker, T. M., Al'Aref, S., & Thandassery, R. B. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156723 · Cited by 1
Boffa, M. B., & Koschinsky, M. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824048-9.00015-8 · Cited by 3
Zhao, L., Tian, X., Lu, J., Zhang, N., Liu, H., Xie, P., & Hongxun, S. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-1220 · Cited by 2
What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
Tsimikas, S. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e7 · Cited by 2
Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a)
Kayıkçıoğlu, M., Özkan, H. S., & Tokgözoğlu, L. S. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i3.21 · Cited by 2
Mykhaloiko, O., & Mykhalojko, I. Y. (2023) · The Ukrainian Biochemical Journal · doi:10.15407/ubj95.01.058 · Cited by 2
Influence of triglyceride concentration in lipoprotein(a) as a function of dyslipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.03.001 · Cited by 6
Elevated Lp(a): Guidance for Identifying and Managing Patients
Hilleman, D. E., Vacek, J. L., & Backes, J. M. (2024) · Southern Medical Journal · doi:10.14423/smj.0000000000001675 · Cited by 2
Pharmacological methods to lower lipoprotein(a) levels
Wierzbowska, N., Olejnik-Wojciechowska, J., Dąbrowska, A., & Żurawska, K. (2024) · Medical Research Journal · doi:10.5603/mrj.99088 · Cited by 2
“It is therefore still necessary to standardize analytical methods and their results [12].”
BackgroundSolnica, B., Sygitowicz, G., Sitkiewicz, D., Cybulska, B., Jozwiak, J. J., Odrowąż‐Sypniewska, G., & Banach, M. (2020) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0014.1296 · Cited by 4
Menambath, D. T., Yalla, D. R., Ashok Prabhu, K., Kuthethur, S., & Mangalore, N. (2021) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v13i2.1312 · Cited by 2
Giesecke, Y., Soete, S., Mackinnon, K., Tsiaras, T., Ward, M., Althobaiti, M., Süveges, T., Lucocq, J. E., McKenna, S. J., & Lucocq, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176373 · Cited by 2
“This approach may be an important refinement because populations such as LDL and Lp(a) are similar in size and morphology and yet have distinctive protein compositions [16,17].”
BackgroundLipoprotein(a) in the advent of a PCSK9 world
Kotani, K. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219884965 · Cited by 2
Lipoprotein(a)—Investigating Sex-Based Differences Across the Lifespan in Men and Women
Driesenga, S., Schikowski, E. M., Koczo, A., Hauspurg, A. K., Countouris, M. E., & Saeed, A. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00768-7 · Cited by 1
“The size of the Lp(a) molecule is highly variable, and different isoforms are attributed to differences in kringle domains [51].”
The distribution of D-amino acid in food and drug and their effects on mouse metabolism
Zhang, Y., Li, X., Zhang, P., Yang, D., Zeng, C., Ji, Y., Zeng, C., Wu, Y., Wang, Q., Liu, Y., et al. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117186 · Cited by 2
Bachmeier, C., Ward, G., Kassianos, A. J., Dechavez, A. C., Ebersohn, C., Liu, A., & Kostner, K. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1605 · Cited by 1
“The Randox assay is based on the Denka assay, which is considered to be amongst the assays to be least isoform-sensitive and most reliable in terms of commercially available methods [5].”
InfluentialClark-McKellar, J., Keteepe‐Arachi, T., Fitzgerald, P., & Ruddock, M. W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1688597 · Cited by 2
“Using a threshold of 75 nmol/L, approximately 25% of Caucasians, 50% of individuals of West African descent, and 10% of Japanese individuals would be classified as having increased cardiovascular risk (15).”
Hsu, H., Fan, H., Tsai, M.-C., Lai, C.-J., Hwang, L. C., & Chien, K. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-0847 · Cited by 3
Tognola, C., Bernasconi, D. P., Rebora, P., Intravaia, R. C. M., Mancusi, C., Visco, V., Cesaro, A., Golia, E., Fucile, I., Merlini, P., et al. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00781-w · Cited by 1
Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review
Ricottini, E., Ciavaroli, N. G., Cristo, A. D., Lentini, A. E., Trunfio, T. A., D’Antonio, L., Mangiacapra, F., Nusca, A., Cammalleri, V., Melfi, R., et al. (2026) · Therapeutics · doi:10.3390/therapeutics3020011 · Cited by 1
“Today, various isoform-insensitive ELISAs have been validated and recommended for the quantification of Lp(a) [47] (Table 1).”
Tsimikas, S., & Marcovina, S. M. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101051 · Cited by 2
“Lp(a) particle numbers in nmol/L were measured using Roche Tina-quant Gen. 2 kit on a Roche c502 analyzer (3).”
Self-citationMustafa, A., Dallaway, A., Lagojda, L., Kite, C., Abdelhameed, F., Chatha, K. K., Suresh, A., Randeva, H. S., & Kyrou, I. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1778393 · Cited by 1
“…color), or low (green color) risk across all included studies. concentrations are primarily governed by variation at the LPA locus, particularly the kringle-IV (KIV) type 2 repeat number that determines apolipoprotein(a) isoform size, which accounts for most inter-individual variability (76).”
Almahmeed, W. A., Sabbour, H. M., Shantouf, R. S., Aljaberi, A. K., Tamimi, H. E., Lootah, F. B., Sayed, N. A., Ali, J. A., Akbar, M. A. J., Shehab, A., et al. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100569 · Cited by 1
“A major challenge lies in the development of antibodies that can reliably detect apo(a) across its diverse isoforms without cross-reacting with structurally similar proteins like plasminogen or apoB [26].”
InfluentialCorrelation between serum and plasma lipoprotein(a) measurements: ARIC study
Bene-Alhasan, Y. O., Sun, C., Hamid, A., Nambi, V., Graff, M., Avery, C. L., Ballantyne, C. M., & Hoogeveen, R. C. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.05.226 · Cited by 1
Mwipatayi, B. P., Dodd, J., Carnagarin, R., Mori, T. A., Golledge, J., Burrows, S., Watts, G. F., Iida, O., & Schlaich, M. P. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70309 · Cited by 1
Lin, L., Brush, M. N., Nelson, C. B., Alexander, V. J., Xia, S., Gordts, P. L. S. M., & Tsimikas, S. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101699 · Cited by 2
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.04.001 · Cited by 1
RetractedLipoprotein(a): Are we ready for large-scale clinical trials?
Zheng, S., Fang, G., Du, J., & Dong, J. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132236 · Cited by 2
Jawi, M. (2024) · Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology/Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology · doi:10.21608/eajbsc.2024.396677 · Cited by 1
Saeed, A., Nambi, V., & Jones, P. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00005-3 · Cited by 2
Rohatgi, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00008-x · Cited by 1
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Aboulmakarim, S., Adarmouch, L., Soumia, H., Hicham, B., Abderrahmane, B., & Chellak, S. (2023) · Annals of Endocrinology and Metabolism · doi:10.36959/433/573 · Cited by 1
Vrablík, M., Šálková, V., Vecka, M., Soška, V., Budina, M., & Šálek, T. (2023) · Biochemia Medica · doi:10.11613/bm.2023.030705 · Cited by 1
“We found that only a small portion of laboratories from Czechia and Slovakia reported high LDL-C re-sults with interpretative comments that considered an FH diagnosis. was developed in molar units (28).”
(DGfN), D. G. F. N., Schettler, V. J. J., (DN), V. D. N., Ringel, J., Jacob, S., Julius, U., Klingel, R., Heigl, F., Roeseler, E., & Grützmacher, P. (2016) · Der Internist · doi:10.1007/s00108-016-0043-9
Durlach, V. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30040-9
Cadegiani, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-52628-3_13 · Cited by 1
Elevated Lipoprotein (a) in Cardiac Outcomes: A Review
Alor, S., Laura, S., Alexander, J., Daniel, F., Mukul, A., Hassan, A., & Singh, S. (2020) · Clinical Cardiology and Cardiovascular Interventions · doi:10.31579/2641-0419/083
“[15] These types of measurements are unfortunately quite common: of the thirty-nine primary prevention studies studied in the systematic review in Lipids in Health and Disease, only twelve studies used isoform independent assays.”
BackgroundMethodChilazi, M. J., Zheng, W., Park, J., Marvel, F. A., Khoury, S. R., Jones, S., & Martin, S. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.006
Lackner, K. J., & Peetz, D. (2018) · Springer eBooks · doi:10.1007/978-3-662-49054-9_1887-1
Lackner, K. J., & Peetz, D. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_1887
Measurement of Lipoprotein(a) in the Clinical Laboratory
SULLIVAN, D. R., Woolnough, C. A., Perera, N., Ramanathan, J., & Badrick, T. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_18
Riesgo aterogénico en la preeclampsia agravada lejos del termino y de aparición tardía
González, J. A. S., Machado, M. G., González, E. Á.-G., & Muñoz, N. L. S. (2023) · Revista de la Federación Centroamericana de Obstetricia y Ginecología · doi:10.37980/im.journal.revcog.20232113
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Self-citationAdvanced Research on Lp(a) and Ischemic Stroke
林, 洁. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361255
Hyperlipoproteinemia (a) and Phytoestrogen Therapy in Dialysis Patients: A Review
Tabibi, H., & Yari, Z. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.017
Lipoproteína (a) y oligonucleótidos antisentido
Romero, J. A. C., Gomez, K. G. C., Ortigoza, M. P. M., & Saavedra-López, H. F. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.3.808
Da, O., Semdé, A., Kouraogo, A., Zongo, E., Sawadogo, A., Zongo, A., Tall, F. G., Fofana, S., Bamba, S., & Ouédraogo, G. A. (2023) · Advances in Biological Chemistry · doi:10.4236/abc.2023.136016
Navigating Lp(a) Measurement Challenges: From Guidelines to Laboratory Perspectives
Parchwani, D. N., Singh, R., & Katoch, C. D. S. (2024) · doi:10.62772/apfcb-news.2024.1.2
“From a technical standpoint, most assays in clinical practice utilize polyclonal antibodies against Lp(a) and are inherently isoform-sensitive [7,14,15].”
Background
Metadata
- Authors
- Marcovina, S. M., & Albers, J. J.
- Affiliations
- University of Washington (US)
- Corresponding author
- Marcovina, Santica M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 57
- Issue
- 4
- Pages
- 526-537
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4808779
- OpenAlex
- W2313206757
- Cited by
- 338
- References
- 49
- Citations by year
- 2026: 44 · 2025: 36 · 2024: 37 · 2023: 45 · 2022: 31 · 2021: 29 · 2020: 35 · 2019: 28 · 2018: 16 · 2017: 26 · 2016: 11
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1631 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), apolipoprotein(a), apo(a) isoforms, immunoassay standardization, antibody specificity, size heterogeneity, assay validation, measurement harmonization, coronary artery disease risk, clinical interpretation
- MeSH terms
- Apolipoproteins A, Cardiovascular Diseases, Data Interpretation, Statistical, Humans, Immunoassay, Reference Standards, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.